ALE.P03
PreclinicalSmall molecule
ALE.P03 is one of 7 small molecule programs targeting Cervical Squamous Cell Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Cervical Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Taxotere
AAvyxa
Approved
Paraplatin
AAvyxa
Approved
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Beyfortus
BeiGenePhase 1
ALE.P03
AAlentis Therapeutics AG
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALE.P03. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAlentis Therapeutics AG